Table 1.

Characteristics of allo-SCT patients used for MiHA T cell expansion assays

Pt	Disease	MiHA T cell response	Sample date (months)	DLI prior to sample date	% MiHA-specific CD8+ T cells
1	MM	HA-1	20 post-SCT	Yes	0.03
2	NHL	HA-1	14 post-SCT	No	0.02
3	AML	LRH-1	12 post-SCT	No	0.04
4	CML-AP	LRH-1	13 post-SCT	Yes	0.47
5	AML	LRH-1	41 post-SCT	Yes	0.02

Characteristics of patients with a hematological malignancy displaying MiHA-specific CD8⁺ T cell responses post-transplantation

Pt patient, AML acute myeloid leukemia, CML-AP chronic myeloid leukemia-accelerated phase, MM multiple myeloma, NHL non-Hodgkin’s lymphoma, SCT stem cell transplantation, DLI donor lymphocyte infusion, given at 4–10 months after allo-SCT